Catalog No.
Product Name
Application
Product Information
Citations
-
E3 ligase ligand-linker conjugate
Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology. - VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
- Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
-
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand -Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. - (S,R,S)-AHPC-(C3-?PEG)?2-?C6-?Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-?PEG)?2-?C6-?Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
-
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. - (S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
- Thalidomide-O-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
-
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. -
ligand-linker conjugate
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. -
Lenalidomide-based Cereblon ligand
Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-PEG4-NHS ester is a PEG-based linker designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). It functions as a ligand for E3 ligases, facilitating targeted protein degradation. This compound is instrumental in chemical biology research aimed at exploring pathways involved in protein turnover and has applications in developing therapeutics for diseases driven by dysregulated protein levels. -
E3 Ligase Ligand-Linker Conjugate
Biotin-Thalidomide is a biotinylated derivative of Thalidomide designed to selectively bind to the cereblon (CRBN) E3 ubiquitin ligase. This compound serves as a crucial ligand-linker conjugate for the development of proteolysis-targeting chimeras (PROTACs). Biotin-Thalidomide facilitates targeted proteasomal degradation of specific proteins, making it a valuable tool for research in targeted protein degradation and molecular biology. Its utility extends to applications in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand combined with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in proteolysis-targeting chimera (PROTAC) applications, facilitating targeted protein degradation by promoting the interaction between the target protein and the E3 ubiquitin ligase. Its unique structure enables researchers to explore novel therapeutic strategies in cellular and molecular biology studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-azide is an E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. It serves as an essential component in PROTAC technology, facilitating targeted protein degradation. This compound is a versatile click chemistry reagent, containing an azide group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN moieties. These properties make it valuable for various bioconjugation applications in chemical biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine 5-fluoride is a synthesized compound that functions as an E3 ligase ligand-linker conjugate, featuring the Thalidomide-derived cereblon ligand. This reagent is designed for applications in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. Its unique structure allows for effective modulation of protein levels in experimental settings, making it a valuable tool in the study of cellular processes and therapeutic development. -
E3 ligase ligand-linker conjugate
Thalidomide-4-O-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that plays a critical role in the targeted protein degradation (PROTAC) system, specifically in dTAG-13 applications. This compound is utilized for its ability to degrade FKBP12F36V and bromodomain and extraterminal (BET) proteins, facilitating the modulation of various cellular processes. Its utility in research allows for advancements in understanding protein function and the development of therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG3-propionic acid is an E3 ligase ligand-linker conjugate that combines the thalidomide-derived cereblon ligand with a three-unit polyethylene glycol (PEG) linker. This compound is utilized in PROTAC technology to facilitate targeted protein degradation by engaging E3 ligases. Its design enables efficient delivery of the cereblon ligand to specific cellular targets, making it valuable for research in protein homeostasis and therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate designed to facilitate the synthesis of dCBP-1. This compound acts as a potent and selective heterobifunctional degrader targeting the p300/CBP proteins, enabling targeted protein degradation for research applications in cellular processes, epigenetics, and cancer biology. Researchers can utilize this conjugate to explore pathways and mechanisms regulated by p300/CBP, advancing the understanding of transcriptional regulation and related therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C6-COOH is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a carbon chain linker, facilitating the development of PROTAC (Proteolysis Targeting Chimera) molecules. This compound engages the cereblon protein, effectively modulating protein degradation pathways. Thalidomide-O-C6-COOH is suitable for research applications focused on targeted protein degradation and exploring the therapeutic potential of PROTAC-based strategies in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that utilizes the Thalidomide-based cereblon ligand in conjunction with a specialized linker designed for PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates targeted protein degradation, enabling the selective modulation of protein levels within cells. It is valuable for researchers investigating protein homeostasis, targeted therapy mechanisms, and the development of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a substrate receptor in the CRL4 ubiquitin-proteasome system. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs), offering a novel approach for selective protein degradation in various biological research applications. Its unique structure allows for the effective modulation of protein levels, making it a valuable tool in cellular biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a specialized linker utilized in PROTAC technology. This compound facilitates selective protein degradation by engaging the E3 ubiquitin ligase pathway, making it a valuable tool for investigating targeted protein modulation and therapeutic applications in cancer research and other diseases. Its structural design enhances its potential in developing targeted protein degradation strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C10-COOH is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived CRBN ligand. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, enabling selective degradation of target proteins. Its biological activity is critical for research applications focused on targeted protein degradation and cellular modulation in various therapeutic contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-C2-amido-C2-COOH is a ligand-linker conjugate targeting the CRBN E3 ubiquitin ligase. This compound is designed for the development of proteolysis-targeting chimeras (PROTACs), specifically facilitating the degradation of CDK2/9. It serves as a valuable tool in research focused on protein degradation pathways and the modulation of cellular processes through targeted protein elimination. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand integrated with a flexible linker tailored for PROTAC (Proteolysis Targeting Chimera) applications. This compound demonstrates the capacity to facilitate targeted protein degradation by recruiting E3 ligases to specific substrates, thereby enhancing the control of protein levels in cellular systems. It is valuable for research in targeted therapy and protein regulation studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-NH-PEG1-COOH TFA functions as an E3 Ligase Ligand-Linker Conjugate that targets Cereblon (CRBN). This compound selectively recruits the CRBN protein, facilitating targeted protein degradation pathways. Thalidomide-4-NH-PEG1-COOH TFA is a critical intermediate in the synthesis of CRBN-based PROTAC molecules, making it valuable for research into novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG1-C2-NH2 is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound features a Thalidomide-derived cereblon ligand that facilitates the recruitment of specific substrates to the ubiquitin-proteasome system. Its linker component is compatible with PROTAC technology, making it a valuable tool for researchers investigating therapeutic strategies aimed at modulating protein levels within cells. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C8-NH2 is a synthetic E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand. This compound serves as a valuable tool in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted degradation of specific proteins in cellular systems. It is widely utilized in studies focusing on protein homeostasis, disease modeling, and therapeutic development in various fields including cancer research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a C8 amido linker. This compound is specifically designed for use in PROTAC technology, facilitating targeted protein degradation by recruiting E3 ligases to specific substrates. Its biochemical properties make it suitable for investigating protein modulation and therapeutic applications in cellular research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG2-C2-NH2 is a conjugate designed for E3 ligase targeting, featuring a Thalidomide-derived cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation by engaging E3 ligases through PROTAC technology. It is suitable for research applications aimed at exploring protein regulation and therapeutic interventions in various diseases. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG1-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker, designed for proteolysis-targeting chimera (PROTAC) applications. This compound facilitates the recruitment of E3 ligases, enabling targeted degradation of specific proteins within cellular environments. It is instrumental in the development of novel therapeutic strategies for modulating protein levels in research studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-Boc is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG4 linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. It exhibits key biological activity by modulating the E3 ligase pathways, making it a valuable tool in the study of protein homeostasis and therapeutic applications in disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amide-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon via its Thalidomide component. This compound is designed for use in PROTAC (proteolysis-targeting chimeras) technology, facilitating the targeted degradation of specific proteins within various biological pathways. Its application in chemical research allows for enhanced studies in protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C2-NH2 is a synthetic E3 ligase ligand-linker conjugate designed to target cereblon, a substrate receptor for the ubiquitin-proteasome system. This compound plays a crucial role in PROTAC technology, facilitating targeted protein degradation by linking a specific protein of interest to the E3 ligase for ubiquitination. Its application enhances the study of protein function and regulation in cellular processes, making it valuable for research in drug development and disease modulation. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG1-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate designed to target cereblon, a substrate receptor for the E3 ubiquitin ligase complex. This compound facilitates the development of PROTAC (proteolysis-targeting chimera) technology, enabling targeted protein degradation in various biological research applications. Its unique structure is instrumental in studying protein interactions and modulation within cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG3-C2-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a cereblon ligand derived from Thalidomide, coupled with a PEG3 linker, facilitating the development of proteolysis-targeting chimeras (PROTACs). Its primary utility lies in modulating protein levels within cellular systems, enabling researchers to investigate protein function and potential therapeutic interventions.
